About Us

Our Mission

We are a clinical stage biotech company committed to protecting patients’ brain health and changing outcomes for a broad range of neurodegenerative diseases through best-in-class diagnostic tools and novel therapies.

Our name, APRINOIA, merges the Latin word for sunlight, “apricum,” with the Greek suffix for the mind, “noia.” Our name reflects our mission—to shed light on ways to better diagnose and treat these dreaded neurodegenerative disorders with a vision that these novel diagnostic tools together with targeted therapies will offer a better future for our patients.

Our Team

Mark Shearman
APRINOIA
Chief Executive Officer
Ming-Kuei Jang
APRINOIA
Founder, Chairman, and President of Asia Operations, Tokyo, Hong Kong, Suzhou
APRINOIA
Chief Medical Officer
Brian Achenbach
APRINOIA
Chief Financial Officer
Masaomi Miyamoto
APRINOIA, Japan
Executive Vice President of R&D and Operations
Lili Zhang, Ph.D.
APRINOIA
Senior Vice President, Head of Preclinical Development
Tzu-Chen Yen, Ph.D
APRINOIA, China
General Manager
Chin-Yin Tai
APRINOIA
Vice President of Neurobiology

Our Partners

We have aligned with renowned organizations and elite research institutions to bring precision medicine to neuroscience and push boundaries in the treatment of neurodegenerative diseases. We will continue to expand our partnerships to further develop therapeutic assets through late-phase clinical studies and commercialization.

scientist in lab - our partners

Research and Development Partners

QST
Samsung Biologics
InSilico Medicine
The Michael J. Fox Foundation

Finance Partners

DAOL Investment
Daiwa Securities Group - DCI Partners
Company K Partners
ShangPharma Innovation
taian
DongCheng Pharmaceutical
Daiwa
In Manus Mundus